News from biodel inc

Oct 05, 2012, 16:00 ET

Biodel to Host Analyst / Investor Research and Development Meeting on October 11th in New York

Biodel Inc. (Nasdaq: BIOD) today announced it will be hosting a meeting for analysts and investors on October 11, 2012 in New York. During the...

Sep 27, 2012, 06:00 ET

Biodel to Present at European Association for the Study of Diabetes on October 2, 2012 in Berlin, Germany

 Biodel Inc. (Nasdaq: BIOD) will present experimental data from its ultra-rapid-acting prandial insulin analog program at the 48th annual...

Sep 13, 2012, 06:30 ET

Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123

Biodel Inc. (Nasdaq: BIOD) today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based...

Aug 10, 2012, 06:00 ET

Biodel to Present at 2012 Wedbush PacGrow Lifesciences Management Access Conference

Biodel Inc. (Nasdaq: BIOD) announced today that management will be presenting an overview of the company's technologies, development programs, and...

Jul 26, 2012, 06:00 ET

Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas

 Biodel Inc. (Nasdaq: BIOD) announced today that the Small Business Innovation Research (SBIR) program of the National Institutes of Health...

Jul 10, 2012, 06:00 ET

Biodel to Present at JMP Securities Healthcare Conference

 Biodel Inc. (Nasdaq: BIOD) announced today that management will be presenting an overview of the Company's technologies, development...

Jun 27, 2012, 06:00 ET

Biodel Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

Biodel Inc. (Nasdaq: BIOD) announced today that it has received notice from the NASDAQ Stock Market that the Company has regained compliance with...

Jun 22, 2012, 09:15 ET

Biodel Announces $18.5 Million Private Placement

 Biodel Inc. (NASDAQ: BIOD) today announced that it has entered into a definitive securities purchase agreement with a group of...

Jun 08, 2012, 16:01 ET

Biodel Obtains Exclusive License to Aegis Therapeutics' Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations

Biodel Inc. (Nasdaq: BIOD) and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Biodel an exclusive worldwide license to...

Jun 05, 2012, 06:00 ET

Biodel Announces Data Presentations at American Diabetes Association Annual Meeting

 Biodel Inc. (Nasdaq: BIOD) will present data from animal and human studies with its ultra-rapid-acting prandial insulin product candidates...

May 10, 2012, 15:32 ET

Biodel Announces Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market

Biodel Inc. (Nasdaq: BIOD) today announced that NASDAQ has approved the Company's request to voluntarily transfer the listing of its shares of...

May 10, 2012, 06:00 ET

Biodel Reports Second Quarter Fiscal Year 2012 Financial Results

 Biodel Inc. (Nasdaq: BIOD) today reported financial results for the second fiscal quarter ended March 31, 2012. Highlights since Beginning...

May 07, 2012, 06:00 ET

Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012

 Biodel Inc. (Nasdaq: BIOD) will issue its second quarter fiscal year 2012 financial results on May 10, 2012.  Following the release of...

May 02, 2012, 06:30 ET

Biodel's Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office

Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering...

Apr 26, 2012, 16:30 ET

Ms. Julia R. Brown and Mr. Davey S. Scoon Join Biodel Board of Directors

 Biodel Inc. (Nasdaq: BIOD) today announced the appointments of Ms. Julia R. Brown and Mr. Davey S. Scoon to its Board of Directors.  The...

Apr 15, 2012, 20:00 ET

Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations

 Biodel Inc. (Nasdaq: BIOD) today announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and...

Mar 14, 2012, 16:00 ET

Biodel to Provide Update on Stabilized Glucagon Program at ROTH Conference Today

Biodel Inc. (Nasdaq: BIOD) today will provide an update on its stabilized glucagon program at the ROTH 24th Annual OC Growth Stock...

Mar 08, 2012, 06:00 ET

Biodel Inc. to Present at ROTH 24th Annual OC Growth Stock Conference on March 14th, 2012

 Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the ROTH...

Feb 08, 2012, 16:00 ET

Biodel Reports First Quarter Fiscal Year 2012 Financial Results

Biodel Inc. (Nasdaq: BIOD) today reported financial results for the first quarter ended December 31, 2011. Dr. Errol De Souza, president and...

Feb 03, 2012, 06:59 ET

Biodel to Report First Quarter Fiscal Year 2012 Financial Results on February 8, 2012

 Biodel Inc. (Nasdaq: BIOD) will issue its first quarter fiscal year 2012 financial results on February 8, 2012.  Following the release...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer